AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19802544 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiming Granule
Number of subjects: 0
Study 19802544 — intervention group
Group type: COMPARATOR
Intervention: Calcium dobesilate capsule
Number of subjects: 0
Study 16763247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (3 times daily for 5 days)
Number of subjects: 119
Study 16763247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily for 5 days)
Number of subjects: 119
Study 15642961 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Artemotil (4.8 mg/kg on day 0 at 0 hours, 1.6 mg/kg at 6 hours, and 1.6 mg/kg/day on days 1-4)
Number of subjects: 56
Study 15642961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Artemotil (3.2 mg/kg on day 0 and 1.6 mg/kg/day on days 1-4)
Number of subjects: 56
Study 15642961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient 151 (high dose regimen)
Number of subjects: 56
Study 11524639 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face instruction
Number of subjects: 210
Study 11524639 — intervention group
Group type: COMPARATOR
Intervention: Video-based instruction
Number of subjects: 210
Study 11524639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 210
Study 9395429 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-diagnosis group (neonatal screening)
Number of subjects: 650341
Study 9395429 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diagnostic methods)
Number of subjects: 650341
Study 11067179 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Towards No Tobacco Use curricula (four different school-based tobacco use prevention curricula)
Number of subjects: 48
Study 11067179 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Towards No Tobacco Use curricula
Number of subjects: 48
Study 11067179 — intervention group
Group type: COMPARATOR
Intervention: Control schools (systematic health education delivered by school personnel)
Number of subjects: 48
Study 3531110 — intervention group
Group type: COMPARATOR
Intervention: XRT + BCNU
Number of subjects: 293
Study 3531110 — intervention group
Group type: EXPERIMENTAL
Intervention: MISO + XRT + BCNU
Number of subjects: 293
Study 3531110 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 293
Study 31657712 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg furosemide
Number of subjects: 12
Study 31657712 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg furosemide
Number of subjects: 12
Study 28837593 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 208
Study 28837593 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly
Number of subjects: 208
Study 28837593 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Readiness Questionnaire
Number of subjects: 208
Study 28837593 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Scale total scores
Number of subjects: 208
Study 25840035 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus daily tailored text messages for 6 months
Number of subjects: 124
Study 25840035 — intervention group
Group type: COMPARATOR
Intervention: Standard care (one-on-one counseling sessions with a dietitian and a physician)
Number of subjects: 124
Study 23359039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop delivery
Number of subjects: 15
Study 23359039 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin-pump therapy (control)
Number of subjects: 15
Study 21982658 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI for STEMI
Number of subjects: 3343
Study 18056753 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counseling on pain management, physical activity, and exercise
Number of subjects: 34
Study 18056753 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy intervention (comparison group)
Number of subjects: 34
Study 17176190 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided group
Number of subjects: 155
Study 17176190 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-encouraged group
Number of subjects: 155
Study 17176190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 14668186 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in a 0.04 mol/l solution in Plegisol
Number of subjects: 35
Study 14668186 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid (Plegisol) cardioplegia
Number of subjects: 35
Study 10969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 126
Study 10969368 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 126
Study 8648016 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg twice daily)
Number of subjects: 0
Study 8648016 — intervention group
Group type: COMPARATOR
Intervention: Albuterol sulfate (4 mg twice daily)
Number of subjects: 0
Study 8648016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1510511 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm heart surgery technique (normothermic group)
Number of subjects: 204
Study 6643332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 7.5 mg/kg by iv infusion
Number of subjects: 58
Study 6643332 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg
Number of subjects: 58
Study 6643332 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 1 mg/kg
Number of subjects: 58
Study 31697304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.625 mg
Number of subjects: 61
Study 31697304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg
Number of subjects: 61
Study 30817604 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group psychotherapy (SGP)
Number of subjects: 160
Study 30817604 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 160
Study 28118231 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg (control group)
Number of subjects: 68
Study 28118231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 15 mg (study group)
Number of subjects: 68
Study 28118231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (5 mg and 15 mg)
Number of subjects: 68
Study 25994974 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stretching exercises
Number of subjects: 60
Study 25994974 — intervention group
Group type: COMPARATOR
Intervention: Usual headache management
Number of subjects: 60
Study 24290111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (vitamin D3) 5000 IU/d for 28 days
Number of subjects: 40
Study 24290111 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 150,000 IU cholecalciferol
Number of subjects: 40
Study 21674388 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-Rehabilitation-roBot (NeReBot) used in substitution of standard proximal upper-limb rehabilitation
Number of subjects: 0
Study 21674388 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard proximal upper-limb rehabilitation)
Number of subjects: 0
Study 19435200 — intervention group
Group type: EXPERIMENTAL
Intervention: Galavit
Number of subjects: 0
Study 19435200 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 16686761 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 343
Study 16686761 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 343
Study 16686761 — intervention group
Group type: COMPARATOR
Intervention: CYA/MMF
Number of subjects: 343
Study 15452302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1250 mg)
Number of subjects: 16
Study 15452302 — intervention group
Group type: COMPARATOR
Intervention: IV methylprednisolone (1 gram)
Number of subjects: 16
Study 11252581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (2xED95, group C2)
Number of subjects: 60
Study 11252581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (4xED95, group C4)
Number of subjects: 60
Study 11252581 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (2xED95, group P)
Number of subjects: 60
Study 8315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (500 mg/m2)
Number of subjects: 35
Study 8315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (120 mg/m2)
Number of subjects: 35
Study 3575355 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 37.5 mg
Number of subjects: 12
Study 3575355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29880342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (sirolimus, tacrolimus, prednisone)
Number of subjects: 23
Study 29880342 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate (mycophenolate, tacrolimus, prednisone)
Number of subjects: 23
Study 28850488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fusion operation
Number of subjects: 49
Study 28850488 — intervention group
Group type: COMPARATOR
Intervention: Multimodal rehabilitation
Number of subjects: 49
Study 24442560 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily
Number of subjects: 1479
Study 24442560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1479
Study 23433739 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab
Number of subjects: 549
Study 23433739 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 549
Study 21338241 — intervention group
Group type: EXPERIMENTAL
Intervention: Immigrant residents (IR)
Number of subjects: 0
Study 21338241 — intervention group
Group type: COMPARATOR
Intervention: Host residents (HR)
Number of subjects: 0
Study 21338241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking and income
Number of subjects: 0
Study 21338241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking and alcohol drinking
Number of subjects: 0
Study 18840372 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of 30 mg sublingual ketorolac
Number of subjects: 27
Study 18840372 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of 30 mg sublingual ketorolac
Number of subjects: 27
Study 16737621 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-margin group (distal margin of 2 cm, proximal margin of 1 cm)
Number of subjects: 152
Study 16737621 — intervention group
Group type: COMPARATOR
Intervention: Narrow-margin group (resection margin < 1 cm)
Number of subjects: 152
Study 12844375 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mmol slow-release KCl/d (n=30)
Number of subjects: 59
Study 12844375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 59
Study 10563527 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-alphaN3 with N-acetyl cysteine 1200 mg/day and vitamin E 600 mg/day
Number of subjects: 120
Study 10563527 — intervention group
Group type: COMPARATOR
Intervention: Natural interferon-alphaN3 alone
Number of subjects: 120
Study 8939377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraperiosteal flap technique
Number of subjects: 0
Study 8939377 — intervention group
Group type: COMPARATOR
Intervention: Push-back technique (Wardill, 1937)
Number of subjects: 0
Study 8939377 — intervention group
Group type: COMPARATOR
Intervention: Mucoperiosteal technique
Number of subjects: 0
Study 1438670 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25
Study 1438670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 25
Study 1438670 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 25
Study 2856817 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 2856817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study 30690400 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed air tower (DAT) sprayer
Number of subjects: 0
Study 30690400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-headed fan tower (MFT) sprayer
Number of subjects: 0
Study 30690400 — intervention group
Group type: COMPARATOR
Intervention: Axial fan airblast (AFA) sprayer
Number of subjects: 0
Study 29580134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 30s (simple set of 30 seconds)
Number of subjects: 36
Study 29580134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 10s (multiple sets of 10 seconds)
Number of subjects: 36
Study 29580134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10s (simple set of 10 seconds)
Number of subjects: 36
Study 27382136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl banner displaying vegetable characters
Number of subjects: 22026
Study 27382136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of television segments and vinyl banners
Number of subjects: 22026
Study 27382136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl banner
Number of subjects: 22026
Study 24887540 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended current (group A)
Number of subjects: 84
Study 24887540 — intervention group
Group type: COMPARATOR
Intervention: Pure coagulation current (group B)
Number of subjects: 84
Study 23230666 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-invasive surgical therapy (endoscope-assisted posterior operation)
Number of subjects: 44
Study 23230666 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical therapy (control group)
Number of subjects: 44
Study 23230666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 20434047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic vessel disease (TEVD)
Number of subjects: 46
Study 20434047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 46
Study 20434047 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TEVD and ICH)
Number of subjects: 46
Study 18758677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture together with tricyclic antidepressants and exercise (n=34)
Number of subjects: 58
Study 18758677 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants and exercise only (n=24)
Number of subjects: 58
Study 16496831 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised education intervention (EI)
Number of subjects: 93
Study 16496831 — intervention group
Group type: COMPARATOR
Intervention: Standard preadmission program (SP)
Number of subjects: 93
Study 14645186 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (routine pre-IVF counselling)
Number of subjects: 141
Study 10476944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 50 IU
Number of subjects: 112
Study 10476944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 15 IU
Number of subjects: 112
Study 10476944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 150 IU
Number of subjects: 112
Study 10476944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8982576 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful long-term follow-up and evaluation of medical interventions in the neonatal period
Number of subjects: 0
Study 1487471 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 1487471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6723694 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release mexiletine 360 mg 12 hourly
Number of subjects: 12
Study 6723694 — intervention group
Group type: COMPARATOR
Intervention: Conventional mexiletine 200 mg 8 hourly
Number of subjects: 12
Study 6723694 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release mexiletine
Number of subjects: 12
Study 6723694 — intervention group
Group type: COMPARATOR
Intervention: Conventional mexiletine
Number of subjects: 12
Study 30672623 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg fixed interval (FI)
Number of subjects: 52
Study 30672623 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg fixed interval (FI)
Number of subjects: 52
Study 30672623 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab (FI)
Number of subjects: 52
Study 30672623 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 52
Study 29857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal acupoint therapy (HAT)
Number of subjects: 32
Study 29857882 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 26687616 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 76
Study 26687616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 76
Study 23332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (Ca/VitD)
Number of subjects: 508
Study 23332626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 22791289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/thalidomide/dexamethasone (VTD)
Number of subjects: 386
Study 22791289 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide/dexamethasone (TD)
Number of subjects: 386
Study 22791289 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B)
Number of subjects: 386
Study 22791289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/thalidomide/dexamethasone (VTD) post-ASCT
Number of subjects: 386
Study 22791289 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide/dexamethasone (TD) post-ASCT
Number of subjects: 386
Study 22791289 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) post-ASCT
Number of subjects: 386
Study 20195673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g/12 h) plus amikacin (15 mg/kg/day)
Number of subjects: 190
Study 20195673 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin
Number of subjects: 190
Study 17624617 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Northland intervention program
Number of subjects: 0
Study 17624617 — intervention group
Group type: COMPARATOR
Intervention: Delayed-program control communities
Number of subjects: 0
Study 15932660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/d)
Number of subjects: 60
Study 15932660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluvastatin)
Number of subjects: 60
Study 11883790 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (30 g/300 ml/30 min)
Number of subjects: 0
Study 10073605 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with glomerulonephritis (GN)
Number of subjects: 37
Study 10073605 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetic nephropathy
Number of subjects: 37
Study 10073605 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdissected glomeruli from patients with GN
Number of subjects: 37
Study 7560615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction
Number of subjects: 3339
Study 7560615 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 3339
Study 7560615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction within 42 days
Number of subjects: 3339
Study 7560615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction between 43 and 365 days
Number of subjects: 3339
Study 7560615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction between 366 days and 3 years
Number of subjects: 3339
Study 2287792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 16 mg orally
Number of subjects: 0
Study 2287792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 4 mg intranasally for 1 week
Number of subjects: 0
Study 2287792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg or 16 mg
Number of subjects: 0
Study 2287792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (general)
Number of subjects: 0
Study 6756709 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 17
Study 6756709 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 17
Study 30877128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred intervention
Number of subjects: 0
Study 30877128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30060900 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid dissection technique
Number of subjects: 29
Study 30060900 — intervention group
Group type: COMPARATOR
Intervention: Traditional dissection technique
Number of subjects: 29
Study 27261986 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused meditation (8-week program with weekly 75 min classes)
Number of subjects: 68
Study 27261986 — intervention group
Group type: COMPARATOR
Intervention: Self-care exercise program (with wait-list offer for meditation)
Number of subjects: 68
Study 27261986 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused meditation
Number of subjects: 68
Study 27261986 — intervention group
Group type: COMPARATOR
Intervention: Self-care exercise program
Number of subjects: 68
Study 25159926 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FMSRP)
Number of subjects: 34
Study 25159926 — intervention group
Group type: COMPARATOR
Intervention: Partial-mouth scaling and root planing (PMSRP)
Number of subjects: 34
Study 22826983 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (fluorouracil, doxorubicin, mitomycin C)
Number of subjects: 50
Study 22826983 — intervention group
Group type: COMPARATOR
Intervention: CDDP, FU/FA (cisplatin, 5‐fluorouracil, leucovorin)
Number of subjects: 50
Study 20586923 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus followed by a 12-h placebo infusion and concomitant 600-mg clopidogrel
Number of subjects: 73